Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build next-gen central nervous system drugs. The research pact—inked with recently ...

Biogen and City Therapeutics are to partner for the development of new RNA interference (RNAi) therapies. Leveraging tissue-enhanced delivery technologies, the partnership will concentrate on one ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs. City Therapeutics will develop its namesake cityRNAs—short for cleavage ...

Biogen recently announced a collaboration with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases, contributing to a 6% share price increase over the past month.

Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop an RNAi trigger molecule combined with proprietary drug delivery technology from ...

Biogen Inc. (NASDAQ:BIIB), a prominent player in the biopharmaceutical industry specializing in neuroscience and rare diseases, finds itself at a critical juncture. According to InvestingPro ...

Biogen and City Therapeutics are collaborating to develop select RNAi therapies in a $46 million partnership. City Therapeutics, a private biopharmaceutical company, will offer its RNAi ...

The BIO convention may be hosted by Boston this year, but that hasn’t stopped other states from getting in on the action.

Biogen and City Therapeutics have announced a partnership worth over $1bn to develop new RNAi therapies. The collaboration will initially centre on a single target that “mediates key central nervous ...

Biogen Inc. and City Therapeutics, Inc. announced a strategic collaboration to develop novel RNA interference (RNAi) therapies targeting central nervous system diseases. City Therapeutics will ...

Biogen Inc, a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives, and City Therapeutics Inc, a privately held biopharmaceutical ...